Compare CPAC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | ALVO |
|---|---|---|
| Founded | 1949 | 2013 |
| Country | Peru | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2003 | N/A |
| Metric | CPAC | ALVO |
|---|---|---|
| Price | $11.70 | $4.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.90 | $8.00 |
| AVG Volume (30 Days) | 56.6K | ★ 698.9K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.49 | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | $19.78 | ★ $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.01 | $2.94 |
| 52 Week High | $12.70 | $9.25 |
| Indicator | CPAC | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 59.65 |
| Support Level | $10.30 | $3.65 |
| Resistance Level | $12.35 | $3.94 |
| Average True Range (ATR) | 0.31 | 0.19 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 30.15 | 96.48 |
Cementos Pacasmayo SAA is a Peruvian cement company, and only cement manufacturer serving in the northern region of Peru. It produce, distribute and sell cement and cement-related materials, such as precast products and ready-mix concrete. Its products are mainly used in construction, which has been one of the fastest growing segments of the Peruvian economy in recent years. It also produce and sell quicklime for use in mining operations. It also provide transportation services. It has three operating segments cement, concrete, mortar, pavement and precast; quicklime; and sales of construction supplies. The majority of profit comes from Cement segment. Peru's cement production is into three regions northern region, central region, including Lima's metropolitan area, and southern region.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.